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Collaboration between networks presents opportuni-
ties to increase analytical power and cross-validate find-
ings. Multivariate analyses of 2 large, international datasets
(MYSTIC and SENTRY) from the Global Advisory on
Antibiotic Resistance Data program explored temporal,
geographic, and demographic trends in Escherichia coli
resistance from 1997 to 2001. Elevated rates of nonsus-
ceptibility were seen in Latin America, southern Europe,
and the western Pacific, and lower rates were seen in North
America. For most antimicrobial drugs considered, nonsus-
ceptibility was higher in isolates from men, older patients,
and intensive care unit patients. Nonsusceptibility to
ciprofloxacin was higher in younger patients, rose with
time, and was not associated with intensive care unit sta-
tus. In univariate analyses, estimates of nonsusceptibility
from MYSTIC were consistently higher than those from
SENTRY, but these differences disappeared in multivariate
analyses, which supports the epidemiologic relevance of
findings from the 2 programs, despite differences in surveil-
lance strategies.
T
he World Health Organization (WHO) highlights the
establishment of “effective, epidemiologically sound
surveillance of antimicrobial resistance among common
pathogens in the community, hospitals, and other health
care facilities” as 1 of 2 fundamental public health priori-
ties in efforts to confront antimicrobial drug–resistant
organisms (1). At present, most data published in the inter-
national literature on antimicrobial resistance are derived
from short-term surveys of specific organisms and agents
in defined areas. Consequences of this nonsystematic, dis-
continuous approach are the inability to establish meaning-
ful baseline trends; low sensitivity in detecting new
threats; inadequate information to evaluate interventions;
and lack of data on organisms, antimicrobial drugs, and
patient populations not included in the surveys.
Surveillance groups must coordinate efforts to provide
the broadest set of data to policymakers and researchers
and to assess the reliability of findings from individual sys-
tems. Recognizing the urgency of the problem and the
value of joint surveillance collaborations, the Alliance for
the Prudent Use of Antibiotics (APUA), a nonprofit organ-
ization, established the Global Advisory for Antibiotic
Resistance Data (GAARD) (2) in 1999 to involve several
of the world’s largest multinational enterprises tracking
global trends in resistance as well as the Centers for
Disease Control and Prevention, WHO, and the WHO
Collaborating Centre for Surveillance of Antimicrobial
Resistance, which serve in advisory roles. Currently,
AstraZeneca International (supporting the Meropenem
Yearly Susceptibility Test Information Collection [MYS-
TIC] surveillance project), Bayer AG (TARGETed),
Bristol-Myers Squibb Company (SENTRY),
GlaxoSmithKline (Alexander Project), and Ortho-McNeil
Pharmaceuticals (TRUST) work with APUA to provide
data for GAARD studies. In 2002, data were collected
from then-participating GAARD members on
Streptococcus pneumoniae (3),  Haemophilus influenzae
(4), and Escherichia coli. The focus of this article is the
analysis of submitted E. coli results from GAARD-partic-
ipating systems tracking E. coli at that time, i.e., MYSTIC
and SENTRY. 
E. coli is the most common cause of infections by
gram-negative bacilli (5) and the bacterial organism most
often isolated from blood cultures (6–9). It is a frequent
cause of outpatient urinary tract infections in women
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septicemia, and of nosocomial infections among hospital-
ized patients. Meningitis caused by E. coli in neonates is
frequently fatal. Resistance to recommended first- and sec-
ond-line agents, such as penicillins, cephalosporins, sulfa
drugs (5,7,10), and fluoroquinolones (11,12) is high in
many countries and is commonly associated with treat-
ment failure (13,14).
Methods
Antimicrobial susceptibility data on E. coli collected by
the MYSTIC and SENTRY systems were forwarded to
GAARD coordinators at APUA for descriptive and infer-
ential analysis of temporal, demographic, and geographic
trends. MYSTIC was launched by AstraZeneca in 1997 to
study bacterial resistance in specialist and general hospital
units in hospitals using meropenem (15). At present, 52
sites from 19 countries are contributing results. Each cen-
ter isolates up to 100 gram-positive and 100 gram-negative
aerobic bacteria per year from routine diagnostic samples
from hospitalized patients, excluding repeat patient iso-
lates. Antimicrobial susceptibility tests are performed by
broth microdilution by using NCCLS reference methods
(16) either on-site (for non-US laboratories) or by a refer-
ence laboratory (for US participants). More than 9,000 iso-
lates are processed annually, with at least 9 antimicrobial
drugs tested per strain. 
Bristol-Myers Squibb established the SENTRY pro-
gram in 1997 as a global program for the surveillance of
resistance in bacterial and fungal populations (17). SEN-
TRYhas expanded from 75 sites in 1997 to 94 laboratories
in 35 countries in 2003. Bacterial isolates are obtained
from diagnostic specimens taken in the course of routine
clinical management of both hospitalized and community
patients. Each site collects a defined number of consecu-
tively identified strains within a number of distinct proto-
cols, e.g., blood isolates, urine isolates, and respiratory
isolates, excluding repeat patient isolates. Strains, includ-
ing basic patient demographic data, are shipped to a coor-
dinating laboratory for centralized identification and
susceptibility testing by broth microdilution panels accord-
ing to NCCLS reference guidelines (16). Forty-five to 50
antimicrobial drugs are monitored each year, with ≈30 test-
ed per strain; >200,000 strains are processed annually.
Available Data
Data on E. coli from 1997 to 2001 were available from
24 countries from the MYSTIC program (4,818 isolates)
and 34 countries from SENTRY(14,819 isolates). Because
20 countries are tested by both systems, this figure repre-
sents 38 countries, as shown in Table 1. Numbers in the
table indicate the number of centers that contributed data
at any point during the 5-year period. Descriptive analyses
and multivariate regressions included data from all coun-
tries, except when data were insufficient (defined as <30
isolates in 2000 and 2001) (18): MYSTIC data from
Bulgaria, Malta, Russia, Switzerland, Hong Kong, and
Thailand and SENTRYdata from Austria, the Netherlands,
Portugal, Russia, Mexico, Uruguay, and China. Data from
both networks were available for 16 countries, but direct
univariate comparisons of findings between the 2 networks
were limited to the 10 countries, shown in Figure 1, with
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“comparison” countries, principally representing North
America and Europe, are Belgium, Canada, Germany,
Greece, Italy, Spain, Sweden, Turkey, the United
Kingdom, and the United States. The United States provid-
ed 17% of the MYSTIC isolates and 46% of the SENTRY
isolates.
Antimicrobial Drugs
For E. coli in the MYSTIC project, either 12 (United
States isolates) or 11 (non-US isolates) antimicrobial drugs
were tested. In SENTRY, 26 antimicrobial drugs were
examined. The following 8 compounds were tested by
both programs and will be referred to as the core antimi-
crobial agents for comparisons between the 2 networks:
cefepime, ceftazidime, ciprofloxacin, gentamicin, imipen-
em, meropenem, piperacillin/tazobactam, and tobramycin.
Because a primary objective of this study is to highlight
the value in contrasting findings from different surveil-
lance programs, most subsequent regression analyses will
focus on these 8 agents.
With the exception of ciprofloxacin, these compounds
are primarily administered as second-line therapy to hospi-
talized patients and not routinely to outpatients. Because
monitoring resistance to first-line agents is essential to
guide empiric treatment decisions, data from the SENTRY
network are also presented for the following compounds
not tested by MYSTIC laboratories: amoxicillin/clavulan-
ic acid, ampicillin, nalidixic acid, nitrofurantoin, tetracy-
cline, and trimethoprim/sulfamethoxazole.
Data Analysis
Similar demographic data were available from both
systems and included patient country, age, and sex; inten-
sive care unit (ICU) or non-ICU location; and specimen
type. Susceptibility test data were recorded as MIC values.
Resistant, intermediate, and susceptible categories were
interpreted according to 2003 NCCLS guidelines (19).
During the period studied, NCCLS breakpoints did not
change for the drugs studied. Strains with a clinical inter-
pretation of resistant or intermediate were considered non-
susceptible in further analyses.
Available data on E. coli from 1997 through 2001 were
sent in Microsoft Excel (Microsoft Corp., Redmond, WA,
USA) format by MYSTIC and SENTRY coordinators to
APUA for analysis. For descriptive data analysis, files
were imported into WHONET 5.2 (World Health
Organization, Geneva, Switzerland) (20). Univariate
analyses by chi-square testing and multivariate logistic
regressions were carried out with Intercooled STATA v. 7
(StataCorp LP, College Station, TX, USA), with null
hypotheses rejected for values of p<0.05 and without
correction for multiple comparisons. Age was categorized
in 10-year intervals, and countries were categorized by
geographic region defined in Table 1. 
Results
Univariate Comparison of Surveillance Networks
Acomparison of the MYSTIC and SENTRY results for
2001 is shown in Figure 1 for the 10 comparison countries.
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Figure 1. Comparison of MYSTIC and SENTRY
rates of Escherichia coli nonsusceptibility rates
in 2001 to antimicrobial drugs tested by both net-
works. Significant findings are indicated with an
asterisk where the MYSTIC estimate is higher
than the SENTRY result and with a plus sign
when the SENTRY estimate is higher. Country
codes are the official 3-letter codes designated
by the International Organization for
Standardization: BEL, Belgium; CAN, Canada;
DEU, Germany; ESP, Spain; GBR, United
Kingdom; GRC, Greece; ITA, Italy; SWE,
Sweden; TUR, Turkey; and USA, United States.
Little resistance was seen with imipenem and
meropenem, and an expanded version of this
figure, including those agents, is available from
http://www.cdc.gov/ncidod/EID/vol11no06/04-
1160-G1.htm.Excluding ciprofloxacin, resistance rates were <10% in
2001 for the core antimicrobial drugs among the compari-
son countries, with the following exceptions: ceftazidime
(11.4%) and gentamicin (15.7%) in Italy (MYSTIC);
tobramycin (21.9%) in Turkey (MYSTIC); and
piperacillin/tazobactam in Spain (10.8%), Sweden
(10.9%), Turkey (11.9%), and the United Kingdom
(20.9%) (MYSTIC). No isolates confirmed resistant to
meropenem or imipenem were found by SENTRY. In the
MYSTIC dataset, 2 isolates (from Mexico and Turkey)
were found to be nonsusceptible to meropenem and 23
(from Belgium, Brazil, Germany, Mexico, Malta, Turkey,
and the United Kingdom) to imipenem. As part of an ongo-
ing protocol for quality assurance, several of these isolates
were subsequently confirmed through centralized testing.
Nonsusceptibility estimates in MYSTIC data were con-
sistently higher than in SENTRY. For the 2001 data, coun-
try-specific comparisons of MYSTIC to SENTRY
nonsusceptibility rates were examined for each antimicro-
bial drug. From the 46 possible comparisons, MYSTIC
estimates were higher than in SENTRY 37 times (80.4%,
sign test p<0.001). Excluding comparisons in which either
rate was equal to 0%, MYSTIC estimates were on average
2.2 times higher than SENTRY values. Subsequent analy-
sis suggests that the principal contributor to the differences
between the surveillance systems would be the higher pro-
portion of ICU patients in MYSTIC (38.0%, n = 1,468)
than in SENTRY (19.5%, n = 2,642). Significant differ-
ences are depicted in Figure 1.
Univariate Temporal Trends in 
E. coli Nonsusceptibility
Temporal trends from several of the comparison coun-
tries are shown in Figures 2, 3, and 4. With the exception
of ciprofloxacin, the antimicrobial drugs tested by both
systems are principally reserved for intravenous use in
hospitalized patients in most countries, and nonsusceptibil-
ity rates for these second-line agents were low worldwide,
with some exceptions. Countries with nonsusceptibility
rates >20% to at least 3 of the core agents by at least 1 of
the systems in 2000 or 2001 include Israel, Poland,
Mexico, Venezuela, Hong Kong, and the Philippines. 
Significant trends (chi-square test for trend without cor-
rection for multiple comparisons, p<0.05) evident in the
SENTRY dataset include increasing susceptibility to
piperacillin/tazobactam in Argentina, Australia, Brazil,
Chile, Israel, and the Philippines; increasing susceptibility
to cefepime in Argentina and Brazil but decreasing suscep-
tibility in Israel; increasing susceptibility to gentamicin in
Brazil and Hong Kong; increasing susceptibility to
tobramycin in Australia and Brazil; and decreasing suscep-
tibility to ciprofloxacin in Belgium, Canada, Colombia,
and the United States. MYSTIC data showed a significant
decreasing trend in nonsusceptibility to ciprofloxacin in
Belgium; susceptibility to piperacillin/tazobactam
decreased in the United Kingdom; and susceptibility to
gentamicin and tobramycin decreased in Israel.
Figure 4 shows trends in nonsusceptibility data in com-
parison countries for a number of antimicrobial drugs test-
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Figure 2. MYSTIC results for compari-
son countries. Annual nonsusceptibility
rates of Escherichia coli isolates,
1997–2001. p<0.05. CAZ, cefta-
zidime; TZP, piperacillin/tazobactam;
GEN, gentamicin; CIP, cipro-floxacin;
TOB, tobramycin; FEP, cefepime. An
expanded version of this figure, includ-
ing data from Canada, Germany,
Greece, and Italy, is available from
http://www.cdc.gov/ncidod/EID/vol11
no06/04-1160-G2.htm.ed only by the SENTRY system commonly prescribed in
the outpatient setting. Nonsusceptibility for multiple first-
line agents was high (approaching or exceeding 50%) in
South Africa, Turkey, Brazil, Chile, Colombia, Venezuela,
Hong Kong, the Philippines, Singapore, and Taiwan.
Noteworthy trends (p<0.05, chi-square for trends without
correction for multiple comparisons) were noted for a
number of these agents. Increasing susceptibility to amox-
icillin/clavulanic acid was seen in Argentina, Brazil,
Canada, Chile, Italy, the United Kingdom, and the United
States. Increasing susceptibility to trimethoprim/sul-
famethoxazole was seen in Singapore, Chile, Australia, the
United States, and Italy, but decreasing susceptibility was
seen in Germany; susceptibility to ampicillin decreased in
Germany, Colombia, and the Philippines but increased in
Chile. Susceptibility to nalidixic acid decreased in
Belgium, Canada, Germany, and the United States; suscep-
tibility to nitrofurantoin increased in Canada, Spain, and
Chile. Susceptibility to tetracycline increased in Italy and
the United Kingdom but decreased in Germany.
Multivariate Trends in E. coli Nonsusceptibility
Multivariate logistic regression was performed to
simultaneously control for the effect of potentially con-
founding variables on nonsusceptibility rates. Independent
variables included region, age group, sex, specimen year,
ICU specimen source, and surveillance system. Table 2
highlights the significant factors. Because of the rarity of
meropenem- and imipenem-resistant isolates in the data-
base, these agents were not studied by logistic regression.
Certain regions (southern Europe, Latin America, and
western Pacific), male sex, older age, and ICU isolates
were consistently (for at least 4 of the 6 drugs) associated
with higher nonsusceptibility rates. North American iso-
lates had lower nonsusceptibility rates (for 5 of the 6
drugs), while isolates from northern Europe had higher
rates only for ciprofloxacin. Significant temporal trends
were identified only with ciprofloxacin (decreased suscep-
tibility over time, odds ratio [OR] 1.14, 95% confidence
interval [CI] 1.07–1.21, p<0.001) and piperacillin/tazobac-
tam (increased susceptibility, OR 0.74, 95% CI 0.68–0.81,
p<0.001). For ciprofloxacin, in contrast to findings with
other agents, younger age was associated with a higher risk
for nonsusceptibility (OR 0.39, 95% CI 0.29–0.52,
p<0.001), and nonsusceptibility was not associated with
ICU status. An important finding of the multivariate analy-
sis is that the surveillance system (MYSTIC vs. SENTRY)
was not associated with nonsusceptibility for any of the
compounds, in contrast to the findings of the univariate
analyses.
Discussion
Through integrated analysis of data from multiple
sources, the GAARD project seeks to realize a number of
benefits: 1) increased statistical power in detecting evolu-
tionary events of public health importance and elucidating
risk factors for resistance emergence and spread; 2)
greater geographic, demographic, and temporal coverage
Escherichia coli Antimicrobial Susceptibility Trends
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Figure 3. SENTRY results for antimi-
crobial agents tested in common with
MYSTIC. Annual nonsusceptibility
rates of Escherichia coli, 1997–2001.
p<0.05. CAZ, ceftazidime; TZP,
piperacillin/tazobactam; GEN, gen-
tamicin; CIP, ciprofloxacin; TOB,
tobramycin; FEP, cefepime. An
expanded version of this figure,
including data from Canada,
Germany, Greece, and Italy, is avail-
able from http://www.cdc.gov/ncidod/
EID/vol11no06/04-1160-G3.htm.of bacterial populations than is possible under any single
system with limited resources; and 3) cross-validation of
findings from complementary data sources with distinct
strategies for site recruitment, patient identification, spec-
imen collection, and laboratory testing, which should
prompt deeper investigation of seemingly discordant find-
ings (21).
For countries in which a direct comparison of results
from the 2 systems was possible, resistance frequencies
from MYSTIC were typically higher than from SENTRY.
In only 2 instances were higher SENTRY estimates signif-
icant (ciprofloxacin in Belgium and Canada). Observation
of such incongruent findings should prompt a focused
review for possible rationales, such as laboratory testing
errors, differences among patient populations sampled, cri-
teria for specimen selection, antimicrobial use patterns, or
local outbreaks of resistant organisms. Because SENTRY
estimates for Belgium reflect the experience of a single
institution while MYSTIC data include results from 9
sites, the MYSTIC results may better reflect the situation
in that country.
One of the most substantial findings of the multivariate
analysis is that the surveillance system was not associated
with nonsusceptibility in any of these compounds, in con-
trast to the findings of the univariate analyses. Thus, the
finding that MYSTIC estimates of nonsusceptibility were
consistently higher than SENTRY isolates in paired com-
parisons may be completely attributable to differences in
the demographics of the patient subpopulations sampled.
In this study, the principal contributor identified was the
proportion of ICU patients represented in the 2 systems.
Such findings should increase confidence in the reliability
and validity of findings reported separately from the 2 pro-
grams. The observation of consistent differences in uncon-
trolled comparisons of results between systems also
highlights the importance of including relevant demo-
graphic information in reports on antimicrobial suscepti-
bility rates.
An arbitrary categorization of countries into relatively
low, medium, and high resistance is shown in Table 3 for a
few key first- and second-line antimicrobial drugs used to
treat E. coli infections. The intervals indicated were select-
ed to provide some degree of separation between groups of
countries using the observed estimates and should not be
interpreted as having a direct clinical implication for ther-
apy decisions. The high rates of resistance to both ampi-
cillin and trimethoprim/sulfamethoxazole in many
countries observed in this study should prompt close
review of treatment success rates in settings in which they
are commonly used in empiric therapy (22). 
The use of surveillance data to guide antimicrobial ther-
apy guidelines is a complicated issue that must address the
constraints of available resources and therapeutic alterna-
tives, local resistance and antimicrobial use patterns, and
potential epidemiologic biases in available data. A number
of studies have addressed empiric and quantitative
approaches for using surveillance data in treatment guide-
lines for urinary tract infections and pyelonephritis, includ-
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Figure 4. SENTRY results for supple-
mental antimicrobial drugs tested only
by SENTRY. Annual nonsusceptibility
rates of Escherichia coli, 1997-2001.
p<0.05. AMC, amoxicillin/clavulanic
acid; AMP, ampicillin; NAL, nalidixic
acid; NIT, nitrofurantoin; TET, tetracy-
cline; SXT, trimethoprim/sulfamethox-
azole. An expanded version of this
figure, including data from Canada,
Germany, Greece, and Italy, is avail-
able from http://www.cdc.gov/nci-
dod/EID/vol11no06/04-1160-G4.htm.ing cost-effectiveness studies and establishing resistance
thresholds to guide therapy decisions (23–27).
Several significant results were noted in the univariate
analyses of temporal trends. Such changes over time could
be due to real shifts in the bacterial populations, changes in
the number or type of participating institutions, changes in
specimen collection practices, or spurious correlations, as
no statistical corrections were made for multiple compar-
isons. The significant decrease to 4 or more agents in
Brazil, Chile, and Italy in particular is worth highlighting
for further exploration; Chile has successfully implement-
ed and enforced new national legislation banning the sale
of antimicrobial drugs without a prescription since 1999,
and this legislation has produced substantial reductions in
total antimicrobial drug use in the country (28).
Significant findings from the multivariate analysis of
core antimicrobial drugs were mentioned above: higher
rates of nonsusceptibility in isolates from ICU patients,
older patients, and male patients and in isolates from Latin
America, the western Pacific, and southern Europe. When
all other variables were controlled for, nonsusceptibility to
ciprofloxacin showed a statistical increase in over time,
while nonsusceptibility to piperacillin/tazobactam
decreased. This decrease in nonsusceptibility to
Escherichia coli Antimicrobial Susceptibility Trends
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univariate analyses and merits further investigation into
contributory factors. While temporal trends in the multi-
variate analysis may reflect, to some degree, the high pro-
portion of US isolates in the SENTRY database,
demographic characteristics of SENTRY isolates within
and outside the United States were comparable, with only
a small but significant difference seen for sex (44.2% [n =
1,058] male in the United States vs. 48.1% [n = 2,331]
male outside the United States for 2001 data, p = 0.034).
The higher rate of nonsusceptibility among isolates
from male patients has been previously noted for
ciprofloxacin resistance (10,12,29) and ascribed to epi-
demiologic differences between men and women with E.
coli infections. Urinary tract infections in male patients are
more frequently complicated or healthcare-associated than
those in the typical female patient, and infection in men
may be associated with higher rates of previous antimicro-
bial drug usage and time in the hospital setting (29).
The finding of higher resistance in isolates from ICU
patients to most agents is not unexpected, given the high
selection pressure exerted by intensive antimicrobial use in
this setting and the ease of transmission of resistant
pathogens on the hands of healthcare workers. The obser-
vation that ICU isolates did not have higher rates of resist-
ance to ciprofloxacin, most frequently used in the
outpatient setting, suggests that risk factors for
ciprofloxacin resistance are distinct from those of the
RESEARCH
880 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005other, principally second-line, agents studied. This
dichotomy was also observed with respect to age. For
ciprofloxacin, in contrast to the other core antimicrobial
drugs, older age was associated with a significant protec-
tive effect, i.e., lower nonsusceptibility (OR 0.39, 95% CI
0.29–0.52, p<0.001), than seen in younger patients. One
hypothesis holds that resistance in certain antimicrobial
drugs, such as intravenous or second-line agents, is more
closely associated with patterns of prescribing in hospitals
and in older patients, while resistance in others, such as
ciprofloxacin, is more correlated with patterns of antimi-
crobial drug use in the community. This hypothesis merits
further investigation in a variety of geographic and clinical
settings (30,31). Given the ubiquity of E. coli as a com-
mensal pathogen in the human gut and in animal popula-
tions, resistance in E. coli may be a sensitive indicator of
distinct therapeutic and nontherapeutic, appropriate and
inappropriate uses of antimicrobial drugs (32). Another
APUA-coordinated project, Reservoirs on Antibiotic
Resistance, is a 5-year scientific collaboration that
addresses this issue by exploring the movement of resist-
ance determinants within commensal bacterial populations
and between commensals and human pathogens (33).
Both the MYSTIC and SENTRY surveillance networks
rely on routinely generated test results, a strategy with
advantages over purely research-oriented, resource-inten-
sive special surveys. These advantages include sustainabil-
ity, more complete organism and geographic coverage,
monitoring of baseline trends, infection control alerts, and
outbreak detection. However, potential biases may be
introduced that must be considered, such as selectively
testing patients whose infections did not respond to treat-
ment or who had more severe disease. Such biases may be
amplified in the outpatient setting and in low-resource
countries where treatment is frequently empiric with limit-
ed diagnostic testing. Results from routinely generated
sample collections could usefully be compared to findings
from periodic validation surveys in which greater
resources are expended in identifying and testing represen-
tative patient populations (34–36).
With antimicrobial resistance continuing to evolve and
present a global public health challenge, appropriately
designed and implemented surveillance systems are a pri-
ority. Collaboration among existing surveillance systems
can improve the quality, breadth, and impact of data for
guiding and evaluating clinical and public health policy.
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